Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRAF V600E-mutant colorectal cancer, drawn from the whole corpus: 20 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No standard therapy after progression on encorafenib and cetuximab.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Resistance through MAPK reactivation and MET amplification is common and untargeted.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Adjuvant use of the targeted doublet in stage III disease is untested.
Non-V600 BRAF mutations have no approved targeted option.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
OS 30.
A milestone in how this cancer is treated.
First-line PFS 54.
A milestone in how this cancer is treated.